Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview

被引：28

作者：

Rezaee, Haleh ^{[1
,2
]}

Pourkarim, Fariba ^{[2
]}

Pourtaghi-Anvarian, Samira ^{[2
]}

Entezari-Maleki, Taher ^{[2
]}

Asvadi-Kermani, Touraj ^{[3
]}

Nouri-Vaskeh, Masoud ^{[4
,5
]}

机构：

[1] Tabriz Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tabriz, Iran

[2] Tabriz Univ Med Sci, Fac Pharm, Dept Clin Pharm, Tabriz, Iran

[3] Tabriz Univ Med Sci, Fac Med, Dept Surg, Tabriz, Iran

[4] Tabriz Univ Med Sci, Immunol Res Ctr, Daneshgah St,POB 5166614766, Tabriz, Iran

[5] Universal Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Tehran, Iran

来源：

PHARMACOLOGY RESEARCH & PERSPECTIVES | 2021年 / 9卷 / 01期

关键词：

adverse reactions; chloroquine; COVID-19; drug-drug interaction; Kaletra; remdesivir; PLUS RIBAVIRIN TREATMENT; PHARMACOKINETIC INTERACTIONS; HEPATITIS-C; RHEUMATOID-ARTHRITIS; PROTEASE INHIBITORS; COINFECTED PATIENTS; HEALTHY-VOLUNTEERS; CHLOROQUINE; TOCILIZUMAB; METABOLISM;

D O I：

10.1002/prp2.705

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.

引用

页数：18

共 50 条

[31] Severe drug-drug interactions in elderly patients on medications frequently used in dermatology
Bouteiller, J.
Carvalho, P.
Commin, M. -h.
Massy, N.
Tetart, F.
Joly, P.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2021, 148 (03): : 183 - 184
[32] DRUG-DRUG INTERACTIONS WITH THE USE OF PSYCHOTROPIC MEDICATIONS
Sloan, Diane M.
Ereshefsky, Larry
CNS SPECTRUMS, 2009, 14 (08) : 1 - 8
[33] Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
Jeong, Eugene
Nelson, Scott D.
Su, Yu
Malin, Bradley
Li, Lang
Chen, You
FRONTIERS IN PHARMACOLOGY, 2022, 13
[34] An overview of psychotropic drug-drug interactions
Sandson, NB
Armstrong, SC
Cozza, KL
PSYCHOSOMATICS, 2005, 46 (05) : 464 - 494
[35] Drug-Drug Interactions Involving Pain Medications
Lisi, Donna M.
US PHARMACIST, 2014, 39 (03) : 65 - 74
[36] A Practical Overview of Drug-Drug Interactions
Juurlink, David
CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2005, 58 : 38 - 38
[37] Analysis of drug-drug interactions: An overview
Shipman, C
ANTIVIRAL RESEARCH, 1996, 29 (01) : 41 - 43
[38] Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
Karazniewicz-Lada, Marta
Glowka, Anna K.
Mikulska, Aniceta A.
Glowka, Franciszek K.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (17)
[39] Potential drug-drug interactions and their associated factors in hospitalized COVID-19 patients with comorbidities
Rahmadani, Imanda Dyah
Irawati, Sylvi
Wibowo, Yosi Irawati
Setiadi, Adji Prayitno
PEERJ, 2023, 11
[40] Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
Igho-Osagie, Ebuwa
Puenpatom, Amy
Williams, Marissa Grifasi
Song, Yan
Yi, Denise
Wang, Jessie
Berman, Richard
Gu, Miley
He, Chujun
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (05): : 509 - 518

← 1 2 3 4 5 →